200 related articles for article (PubMed ID: 37950153)
21. An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer.
Li M; Li W; Yang X; Wang H; Peng Y; Yin J; Lu Y; Liu L; Shang J; Zhao Q
Life Sci; 2020 Nov; 261():118368. PubMed ID: 32888940
[TBL] [Abstract][Full Text] [Related]
22. MTUS1 is a promising diagnostic and prognostic biomarker for colorectal cancer.
Cheng LY; Huang MS; Zhong HG; Ru HM; Mo SS; Wei CY; Su ZJ; Mo XW; Yan LH; Tang WZ
World J Surg Oncol; 2022 Aug; 20(1):257. PubMed ID: 35962436
[TBL] [Abstract][Full Text] [Related]
23. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 and PD-L2 expression in colorectal cancer.
Zeynep O; Funda C; Evrim Y; Deniz A; Bülent Y; Fatih YN
Indian J Pathol Microbiol; 2023; 66(1):31-37. PubMed ID: 36656207
[TBL] [Abstract][Full Text] [Related]
25. Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy.
Chu XD; Bao H; Lin YJ; Chen RX; Zhang YR; Huang T; He JS; Huangfu SC; Pan YL; Ding H
Front Immunol; 2022; 13():965492. PubMed ID: 36389685
[TBL] [Abstract][Full Text] [Related]
26. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
[TBL] [Abstract][Full Text] [Related]
27. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
[TBL] [Abstract][Full Text] [Related]
28. Long Noncoding RNA KCNQ1OT1 is a Prognostic Biomarker and mediates CD8
Lin ZB; Long P; Zhao Z; Zhang YR; Chu XD; Zhao XX; Ding H; Huan SW; Pan YL; Pan JH
Int J Biol Sci; 2021; 17(7):1757-1768. PubMed ID: 33994860
[No Abstract] [Full Text] [Related]
29. Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer.
Wang QQ; Zhou YC; Zhou Ge YJ; Qin G; Yin TF; Zhao DY; Tan C; Yao SK
World J Clin Cases; 2022 Aug; 10(22):7686-7697. PubMed ID: 36158487
[TBL] [Abstract][Full Text] [Related]
30. Identification of a Novel Ferroptosis-Related Gene Prediction Model for Clinical Prognosis and Immunotherapy of Colorectal Cancer.
Yang YB; Zhou JX; Qiu SH; He JS; Pan JH; Pan YL
Dis Markers; 2021; 2021():4846683. PubMed ID: 34868393
[TBL] [Abstract][Full Text] [Related]
31. Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer.
Wang C; Weng M; Xia S; Zhang M; Chen C; Tang J; Huang D; Yu H; Sun W; Zhang H; Lai M
Cancer Sci; 2021 Jan; 112(1):178-193. PubMed ID: 33058325
[TBL] [Abstract][Full Text] [Related]
32. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
33. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment.
Chung BS; Liao IC; Lin PC; Wu SY; Kang JW; Lin BW; Chen PC; Chan RH; Lee CT; Shen MR; Chen SH; Yeh YM
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362062
[TBL] [Abstract][Full Text] [Related]
35. An immune-related gene prognostic index for predicting prognosis in patients with colorectal cancer.
Li C; Wirth U; Schardey J; Ehrlich-Treuenstätt VV; Bazhin AV; Werner J; Kühn F
Front Immunol; 2023; 14():1156488. PubMed ID: 37483596
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.
Nie H; Yu Y; Wang F; Huang X; Wang H; Wang J; Tao M; Ning Y; Zhou J; Zhao Q; Xu F; Fang J
Cancer Immunol Immunother; 2024 Jun; 73(8):156. PubMed ID: 38834869
[TBL] [Abstract][Full Text] [Related]
37. Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
Enkhbat T; Nishi M; Takasu C; Yoshikawa K; Jun H; Tokunaga T; Kashihara H; Ishikawa D; Shimada M
Anticancer Res; 2018 Jun; 38(6):3367-3373. PubMed ID: 29848685
[TBL] [Abstract][Full Text] [Related]
38. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
39. Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis.
Chen YF; Yu ZL; Lv MY; Cai ZR; Zou YF; Lan P; Wu XJ; Gao F
Mol Med; 2021 Oct; 27(1):139. PubMed ID: 34717544
[TBL] [Abstract][Full Text] [Related]
40. Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: Relationship with sidedness, clinicopathological parameters, and survival.
Mokhtari Z; Rezaei M; Sanei MH; Dehghanian A; Faghih Z; Heidari Z; Tavana S
Front Oncol; 2023; 13():1069696. PubMed ID: 37035199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
